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OBJECTIVES We analyzed the effects of vascular brachytherapy (VBT) on ostial in-stent restenosis (ISR).
BACKGROUND In-stent restenosis has a high recurrence rate after percutaneous reintervention. The
recurrence rate of ostial ISR lesions and the impact of VBT remain unknown.
METHODS We evaluated 133 patients with native coronary ostial ISR from a pooled database of 990
patients enrolled in randomized VBT trials. Independent quantitative angiography was
performed at baseline and follow-up in 45 gamma, 27 beta, and 61 placebo patients.
RESULTS Binary restenosis was significantly higher in placebo than radiated patients (75.4% vs. 17.8%
in gamma vs. 22.2% in beta, p  0.0001). The treatment effect of both gamma (odds ratio
[OR] 0.06; 95% confidence interval [CI] 0.02 to 0.17) and beta VBT (OR 0.10; 95% CI 0.03
to 0.31) was maintained after controlling for differences in baseline lesion length. Proximal
and distal radiation edge restenosis rates were similar among the groups. Vascular brachy-
therapy of true aorto-ostial lesions (n 34) was similarly beneficial: restenosis rates of placebo
versus gamma or beta patients of 83.3% versus 6.7% versus 28.6%, p  0.0002.
CONCLUSIONS Conventional treatment of ostial ISR is associated with a recurrence rate of over 75%.
Vascular brachytherapy with either gamma or beta sources results in significant and similar
reductions in restenosis compared with placebo. Similar benefits after VBT prevail in true
aorto-ostial lesions. (J Am Coll Cardiol 2003;41:1725–31) © 2003 by the American
College of Cardiology Foundation
Treatment of ostial lesions is one of the challenges of
percutaneous coronary intervention, in part because ostial
lesions are technically difficult to treat and in part because
restenosis rates are high (1,2). Although stents have im-
proved acute results and long-term outcomes (3,4), in-stent
restenosis (ISR) occurs more often after treatment of ostial
lesions compared with non-ostial lesions (5). In-stent reste-
nosis lesions are another challenge to conventional percuta-
neous intervention, primarily because of high recurrence
rates (6,7). However, there are few data about the recurrence
rate after conventional treatment of ostial ISR lesions.
Vascular brachytherapy (VBT) significantly decreases recur-
rence rates after treatment of ISR (8–12). However, there
are also few data about the effect of VBT in ostial ISR
lesions. This angiographic study evaluates the effects of
gamma or beta VBT in ostial ISR lesions.
METHODS
Study population. From an angiographic database of 990
patients enrolled in several randomized VBT trials for the
treatment of ISR, 133 patients were identified with ostial
lesions of a native coronary artery. An ostial lesion was any
lesion within 3 mm of the origin of a major epicardial native
coronary ostium. An aorto-ostial lesion was an ostial lesion
located at the origin of the left main or right coronary artery
(13). Forty-five lesions were treated with gamma (iridium
92 [92Ir]), 27 lesions were treated with beta VBT (strontium
90/yttrium 90 [90S/90Y]), and 61 lesions did not receive
radiation (placebo group). No centering device was used in
either the gamma or the beta radiation groups. The different
trials had different protocols including dose prescriptions
and pre-VBT treatment strategies (Table 1) (8–12). Of
importance, the angiographic inclusion criteria were similar
among the trials except for lesion length.
Angiographic analysis. Cineangiograms were acquired in
multiple, matched projections before percutaneous coronary
intervention (PCI), after final treatment of ISR (following
VBT), and at six to nine months follow-up, or sooner if
recurrent ischemia occurred. Intracoronary nitroglycerin, 50
to 200 mg, was given before angioplasty unless there were
clinical contraindications to its use.
All procedural and follow-up cineangiograms were ana-
lyzed independently by a single Angiographic Core Labo-
ratory (Cardiovascular Research Foundation). Analysts were
blinded to the treatment strategy. Standard morphologic
criteria were used to characterize baseline lesion complexity
using the American College of Cardiology/American Heart
Association lesion complexity scoring system and to identify
the occurrence of angiographic complications. Lesion
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length was determined by the “shoulder-to-shoulder” extent
of obstruction at baseline and follow-up. Quantitative cor-
onary angiography (QCA) was performed using the CMS-
GFT algorithm (MEDIS, Leiden, The Netherlands)
guided by analysts’ drawing of the arterial segment and its
side branches, demonstrating the precise location of the
baseline stenosis, and the positions of the radiation delivery
source (14,15). Inter- and intraobserver variability have been
reported ranging from 0.07 to 0.10 mm for minimal lumen
diameter and 2.7% to 5.1% for percent diameter stenosis
even when using the most precise angiographic systems
(16–19). The contrast-filled injection catheter was used for
image calibration. The minimum lumen diameter (MLD)
and the mean reference diameter (RD), obtained from
averaging a 5-mm segment proximal and distal to the final
ribbon or injured and margin location, were used to calcu-
late the percent diameter stenosis (DS  [1  MLD/RD]
 100).
A MLD of 0 mm was imputed for total occlusions at
baseline or follow-up. Acute gain was defined as the change
in the MLD from baseline to the final post-PCI angiogram;
late loss was defined as the change in MLD from the final
post-PCI angiogram to follow-up. Loss index was calcu-
lated as the slope of the best-fit line from regression analysis
plotting the late loss versus acute gain. Binary restenosis was
defined as a 50% DS at follow-up.
Side branches of main ostial lesions were systematically
assessed with electronic handheld calipers before and after
each intervention, as well as at follow-up. Only vessels
1.5 mm in diameter measured at the most normal and
proximal segment to the main branch were considered as
side branches. The side branch percent DS was calculated in
relation to the reference size of the side branch.
A decay of the radiation dose occurs at the edges of the
source (radiation fall-off). The decrease in dose secondary to
radiation fall-off has been implicated in VBT failure. The
segments defined as radiation fall-off zones were identified
and systematically analyzed (20,21). Radiation fall-off zones
were defined as a 10-mm segment, 5 mm immediately
inside and 5 mm immediately outside the proximal and
distal source markers. The MLD at each fall-off zone was
determined. The mean vessel RD was used to calculate the
DS percent for proximal and distal radiation dose fall-off.
Dose fall-off restenosis was defined by a DS percent in the
dose fall-off area 50%.
Statistical analysis. Angiographic data were independently
analyzed by the Cardiovascular Research Foundation Data
Coordinating Center. Statistical analysis was performed
using SAS software (SAS Institute Inc., Cary, North
Carolina). Categorical data are presented as percent fre-
quencies and compared by chi-square statistics. Continuous
variables are presented as mean  1 SD and compared
across the three treatment groups with one-way analysis of
variance; post-hoc comparison between individual groups
was performed using the Bonferroni correction where p 
0.0167 is the threshold for significance. Stepwise logistic
regression analysis was used to test for a treatment effect
while controlling for differences in angiographic and proce-
dure variables including baseline reference vessel diameter,
lesion length, final MLD, final %DS, acute gain, stent use,
aorto-ostial location, vessel treated, treatment used (gamma
VBT vs. placebo, beta VBT vs. placebo), and additional
stent use.
RESULTS
Baseline angiography and procedure results. Lesion
complexity was similar for all three groups. Qualitative and
quantitative procedural data are shown in Table 2. Although
lesion length was significantly longer in placebo compared
with beta VBT groups, baseline reference vessel diameter,
MLD, and DS percent were well matched. Restenting was
Abbreviations and Acronyms
CI  confidence interval
DS  diameter stenosis
GM  geographic miss
92Ir  iridium 92
ISR  in-stent restenosis
MLD  minimal lumen diameter
OR  odds ratio
PCI  percutaneous coronary intervention
QCA  quantitative coronary angiography
RD  reference diameter
90Sr/90Y  strontium 90/yttrium 90
VBT  vascular brachytherapy
Table 1. Protocol Similarities and Differences Among the Analyzed Clinical Trials
GAMMA-1 WRIST Long WRIST START START 40/20
# of patients (radiated/placebo) 23/12 14/11 8/12 18/26 9/0
Radiation source Gamma Gamma Gamma Beta Beta
Dose (Gy)/depth (mm) 8–30* 15/2 15/2 18–23/2 18–23/2
Lesion length (mm) 45 47 36–80 20 20
Vessel size (mm) 2.74–4.0 3.0–5.0 3.0–5.0 2.74–4.0 2.74–4.0
SVG N Y Y N N
Total occlusion N Y Y Y Y
Plavix/ticlopidine duration (days) 60 30 30 60 60
New stent allowed Y Y Y Y Y
*The dose in GAMMA-1 was prescribed to the adventitia and the distance measured with intravascular ultrasound.
SVG  saphenous vein graft.
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most frequent in gamma-radiated patients and least fre-
quent in beta-treated patients, as a result of protocol
differences. Although final angiographic results were slightly
superior in placebo and gamma compared to beta patients,
the differences were not significant.
Angiographic follow-up. Follow-up QCA results are
shown in Table 3. Placebo-treated lesions had a significantly
smaller follow-up MLD and higher DS percent compared
with both radiation groups. Follow-up QCA measurements
of gamma- and beta-irradiated lesions were similar.
Although acute gain was similar among all three groups,
late loss was significantly higher in placebo compared to
both radiated groups. Consequently, loss index was similar
in gamma- and beta-treated lesions and significantly higher
in the placebo group. The binary restenosis rate for gamma-
irradiated lesions was 17.8% (vs. gamma controls, 77.1%,
p  0.0001) and for beta-irradiated lesions was 22.2% (vs.
beta controls, 73.1%, p 0.0005). Gamma and beta control
patients had similar restenosis rates (77.1% vs. 73.1%, p 
0.9). Both control groups combined had a significantly
higher restenosis rate compared to gamma- and beta-
irradiated lesions (75.4% vs. 17.1% vs. 22.2%, p  0.0001).
Regardless of the source utilized, VBT-treated patients had
a 75% relative reduction in binary angiographic restenosis
rate compared to placebo. By logistic regression analysis the
treatment effect of both gamma (odds ratio [OR] 0.06; 95%
confidence interval [CI] 0.02 to 0.17) and beta VBT (OR
0.10; 95% CI 0.03 to 0.31) was maintained after controlling
for differences in baseline lesion length of the placebo and
VBT groups.
There were 34 true aorto-ostial lesions: 3 in the left main
coronary artery and 31 in the right coronary artery. Aorto-
ostial lesions showed similar baseline angiographic and final
QCA parameters among the three groups. At follow-up,
the aorto-ostial lesions of both the gamma and beta controls
had the same restenosis rate (83.3%). Both placebo groups
combined had a significantly higher restenosis rate com-
pared to either gamma or beta VBT aorto-ostial lesions
(83.3% vs. 6.7% vs. 28.6%, p  0.0002). The difference in
restenosis rate between gamma and beta aorto-ostial treated
lesions was not statistically significant (p  0.46).
Lesion length. In general, lesions were shorter at
follow-up (Fig. 1). The lesion length reduction from base-
line to follow-up was significant for both gamma (14.9 






(n  61) p Value
Lesion location (%)
LAD 4 (8.9)* 10 (37)* 11 (18) 0.012
LCX 22 (48.9) 9 (33.3) 34 (55.7) 0.15
RCA 18 (40) 8 (29.6) 14 (22.9) 0.16
Left main trunk 1 (2.2) 0 (0) 2 (3.3) 1.0
Aorto-ostial 15 (33.3) 7 (25.9) 12 (19.6) 0.31
ACC/AHA  B2 (%) 33 (73.3) 23 (85.1) 52 (85.2) 0.11
Lesion length (mm) 14.9  9.5† 15.2  8.3† 19.4  5.9 0.04
Reference vessel (mm) 2.71  0.39 2.64  0.66 2.61  0.44 0.70
Pre MLD (mm) 0.92  0.48 0.81  0.25 0.82  0.35 0.31
Pre DS% 66.0  16.5 68.5  9.6 67.9  13.4 0.70
Final MLD (mm) 2.03  0.39 2.17  0.54 2.00  0.40 0.23
Final DS% 26.9  14.5 20.8  13.6 26.9  12.5 0.11
Acute gain (mm) 1.11  0.53 1.39  0.54 1.17  0.49 0.12
Stent (%) 27 (60)† 4 (14.8)† 26 (42.6)  0.0001
*Gamma and beta vascular brachytherapy (VBT) versus placebo; p 0.0008; †gamma VBT versus placebo and beta VBT versus
placebo; p  0.0001.
ACC/AHA  American College of Cardiology/American Heart Association; DS%  diameter stenosis percent; LAD 
left anterior descending coronary artery; LCX left circumflex coronary artery; MLDminimal lumen diameter; RCA right
coronary artery.






(n  61) p Value
Lesion length (mm) 6.9  3.6* 4.2  2.4† 16.7  12.1 0.001
MLD (mm) 1.72  0.62† 1.85  0.77† 1.07  0.61  0.0001
DS% 35.7  22.0† 30.9  24.4† 61.8  20.1  0.0001
Restenosis rate (%) 8 (17.8)† 6 (22.2)† 46 (75.4)  0.0001
Total occlusions (%) 2 (4.4) 1 (3.7) 5 (8.2) 0.71
Late loss (mm) 0.31  0.58† 0.31  0.60† 0.94  0.57  0.0001
Loss index 0.30  0.78‡ 0.23  0.47‡ 1.20  2.25 0.004
There were no statistically significant differences comparing placebo patients from gamma- (n 35) versus beta-irradiation (n
26) trials. *Gamma versus placebo; p  0.0001; †gamma versus placebo and beta versus placebo; p  0.0001; ‡gamma versus
placebo and beta versus placebo; p  0.005.
Abbreviations as in Table 2.
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9.5 to 6.9  3.6, p  0.001) and beta (15.2  8.3 to 4.2 
2.4, p  0.001) groups; the difference was not significant in
placebo-treated lesions (19.4  5.9 to 16.7  12.1, p 
0.18).
Irradiated aorto-ostial lesions presented a trend towards a
significant reduction in lesion length from baseline to
follow-up (gamma: 12.9  9.6 to 6.1  2.6, p  0.07; beta:
9.4  6.3 to 3.3  2.1, p  0.1). Conversely, placebo
aorto-ostial lesions presented an increase in the length that
was not significant (15.6  12.7 to 18.9  20.4, p  0.7).
Side branch analysis. Side branches involved in the ostial
ISR lesions had similar baseline DS percent (25.6 31.4 vs.
17.4  3.9 vs. 18.8  28.6, p  0.7) and final DS percent
(29.9  31.9 vs. 30.0  36.8 vs. 31.3  39.9, p  0.4) in
the gamma, beta, or placebo groups, respectively. At follow-
up, there was an increase in side branch DS percent in
irradiated lesions that did not reach statistical significance.
There was no increase in side branch DS percent in placebo
lesions (Fig. 2).
Fall-off zones analysis. From the total group of 133
lesions, only 121 were technically suitable for radiation dose
fall-off analysis because of poor acquisition quality in which
the fall-off zones were not adequately visualized. In addi-
tion, in aorto-ostial lesions as well as in some ostial left
anterior descending and left circumflex coronary artery
lesions, the proximal edge of the radiation source was
located inside the guiding catheter, such that the ostium
received the full prescribed dose; as a result, a subtherapeutic
fall-off zone was present in 76% of the proximal lesions
assessed (Fig. 3). The distal fall-off segment could be
analyzed in all lesions at baseline; only 91.4% could be
analyzed at follow-up either because of total occlusions or to
inadequate contrast filling of the distal arterial segment.
Overall the dose fall-off restenosis rate was significantly
higher for placebo compared with beta or gamma VBT-
treated patients (30% vs. 11.5% vs. 7.4%, p  0.009).
Proximal and distal radiation dose fall-off restenosis are
displayed separately in Figure 4. In the subgroup of aorto-
ostial lesions, there was no recurrence located at the proxi-
mal or distal dose fall-off of the radiation source.
DISCUSSION
Ostial lesions, whether true aorto-ostial or non–aorto-ostial,
have higher restenosis rates compared to non-ostial lesions
after conventional percutaneous intervention (1,2). Vessel
Figure 1. Comparison of the angiographic lesion length at baseline and follow-up in gamma-, beta-, and placebo-treated patients. VBT  vascular
brachytherapy.
Figure 2. Side branch angiographic diameter stenosis (DS %) post-intervention and at follow-up. White bars gamma vascular brachytherapy (VBT) (n
13); striped bars  beta VBT (n  6); black bars  placebo (n  21).
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wall elastic recoil plays an important role in the restenotic
process after balloon percutaneous transluminal coronary
angioplasty in ostial lesions (22). Because stents have over-
come the elastic component, the higher restenosis rates for
ostial lesions can only be explained by exaggerated intimal
hyperplasia. In-stent restenosis lesions have a higher recur-
rence rate compared with de novo lesions (6,7). Although
angiographic predictors of recurrence after ISR intervention
have been reported (7), there are no data regarding the
outcome of ostial ISR lesions after percutaneous interven-
tion. In the current report, the data from the placebo
patients show that ostial location increases the likelihood of
recurrence after an ISR lesion is treated with conventional
techniques. The recurrence rate (75%) resembles the high
recurrence rates reported in other complex ISR lesion
subsets such as proliferative and totally occluded lesions
(7,23,24).
Adjunctive VBT has consistently demonstrated signifi-
cant reductions in restenosis rates compared to conventional
PCI for treatment of ISR. The Multicenter trial of localized
radiation therapy to inhibit restenosis after stenting
(GAMMA-I), SCRIPPS coronary radiation to inhibit pro-
liferation post-stenting trial (SCRIPPS), Intracoronary
brachytherapy to prevent recurrence of restenosis following
angioplasty in patients with in-stent restenosis (WRIST),
Stents and radiation therapy trial (START), Stents and
radiation therapy trial 40/20 (START 40/20), and Ran-
domized double-blind sham-controlled evaluation of the
Guidant intravascular radiotherapy (INHIBIT) trials
showed restenosis rates ranging from 45% to 60% in the
placebo arms. Conversely, in the radiated arms restenosis
rates ranged between 15% and 32%, representing a relative
restenosis reduction of approximately 50% (8,9,12,25,26).
In the current analysis, despite an extraordinarily high
recurrence rate in placebo patients (75%), recurrence in
irradiated patients (18% to 22%) was similar to that ob-
served in most radiation trials enrolling a wide spectrum of
patient and lesion subsets. Furthermore, in the ostial lesion
subgroup, the reduction in recurrence (75%) was greater
than that observed in each of the overall randomized trials.
Thus, radiation therapy appears to mitigate the unfavorable
impact of ostial lesion location on restenosis; a finding
Figure 3. Frequency of the proximal radiation fall-off zone occurring or not occurring in the analyzed population. According to the location of the proximal
edge of the radiation source in relation to the coronary vasculature, the proximal radiation fall-off zone (represented by the ellipse surrounding the proximal
source edge) was either present (right) or not present (left).
Figure 4. Rate of restenosis (RS) occurring at the proximal and distal radiation fall-off zones in gamma-, beta-, and placebo-treated patients. The rates of
restenosis where a fall-off of the radiation dose occurs (ellipse surrounding each radiation source edge) are shown in the graphic. Black bars  gamma
vascular brachytherapy (VBT); striped bars  beta VBT; black bars  placebo.
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similar to a previous subgroup analysis which showed an
enhanced benefit of brachytherapy in other high-risk groups
of patients, such as diabetics, who have exaggerated neoin-
timal hyperplasia (27,28).
One previous report also indicated a higher rate of
restenosis after treatment of aorto-ostial lesions compared
to the other ostial lesions after conventional PCI (2).
Although this previous report did not assess ISR lesions, the
current study shows that the VBT treatment effect was
similar for aorto-ostial and non–aorto-ostial ISR lesions.
High rates of recurrence located at the fall-off zones have
been reported as a limitation for VBT (20,21). Vessel wall
injury at the radiations’ fall-off zones or beyond is known as
geographic miss (GM) (29). Although GM has been
implicated, the specific factors accounting for restenosis
occurring in fall-off zones have not yet been defined.
However, it is well know that vessel wall injury produces
intimal hyperplasia (30); thus, limiting the extent of injury
to the lesion proper with or without radiation therapy is
generally a valuable practice. The higher restenosis rates
observed in the proximal compared with the distal fall-off
segments among the three groups likely represent a combi-
nation of the higher recoil and more aggressive remodeling
associated with the ostial compared to non-ostial location.
The higher restenosis in the proximal dose fall-off location
of placebo patients can be explained by: 1) a radiation
treatment effect, albeit subtherapeutic; and 2) the apparent
change in the pattern of restenosis caused by VBT. Placebo
patients presented at follow-up a more aggressive and
diffuse pattern with long restenotic lesions as in baseline,
whereas radiated patients presented a more focal pattern
with restenotic lesions significantly shorter than baseline
(Fig. 1).
Whether a therapeutic or subtherapeutic radiation dose
combined with vessel wall injury could stimulate intimal
proliferation in side branches is not well known. The
current analysis did not show a significant difference in
follow-up side branch diameter stenosis among the three
groups; however, although not statistically significant, side
branches that received radiation tended to have an increase
in DS% whereas placebo-treated vessels tended to show a
decrease in DS%. This is consistent with previous reports
(31,32).
Study limitations. There are several limitations to this
study. This is an angiographic study; therefore, only patients
who completed the angiographic follow-up were assessed.
(The angiographic follow-up rates were as follows:
GAMMA-1, 84.7%; WRIST, 90.7%; Long WRIST,
80.3%; START, 82%; and START 40/20, 81%.) Patients
from different study protocols were combined; although the
inclusion criteria were similar, there were differences with
regards to lesion length and treatment strategies allowed.
However, across the trials the restenosis rates in the placebo
patients ranged from 63% to 92% and in the irradiated
patients from 9% to 33%. The number of patients in each
group (placebo, gamma-irradiated, and beta-irradiated) is
small; this should be considered when interpreting the
results. At the time some of the trials were conducted, the
importance of limiting vessel injury and GM was not
recognized; therefore, the extent of injury was not assessed
prospectively and GM was not systematically analyzed. For
similar reasons, the quantitative assessment of the dose
fall-off zones was a post-hoc analysis. At the time of these
trials, the association between new stent deployment during
VBT and stent thrombosis and recurrence was not known.
Although it is not currently recommended, restenting was
allowed in all of these clinical studies. However, the rest-
enting rate in the beta-irradiation trials in the current
analysis was 15% versus 60% in the gamma-irradiation trials
whereas the late thrombosis and recurrence rates were
similar. Finally, a systematic IVUS analysis in all patients
would provide the needed data to understand the mecha-
nisms of fall-off segment restenosis, especially in the prox-
imal ostial location; this was not performed.
Conclusions. This post-hoc analysis of patients from mul-
tiple VBT trials showed that ostial ISR lesions have a
malignant outcome after conventional PCI, with a 75%
recurrence rate. Adjunct vascular brachytherapy, with either
gamma or beta VBT, equalizes the poor outcome of this
complex lesion subset to the outcome of non-ostial ISR
lesions treated with brachytherapy. Similar benefits are
demonstrated in pure aorto-ostial lesions. More data—
ideally, a prospective trial—would help to substantiate these
findings as well as to understand the effects of radiation on
side branches arising adjacent to ostial lesions.
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